Advanced searches left 3/3

Cyclophosphamide - PubMed

Summarized by Plex Scholar
Last Updated: 27 June 2022

* If you want to update the article please login/register

Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.

The optimal conditioning regimen for acute myeloid leukemia with post transplantation cyclophosphamide remains unclear. Alternatively, a reduced intensity conditioning regimen involving thiotepa and reduced-dose busulfan with fludarabine may reduce AML relapses. In two separate populations based on age, we retrospectively compared CyFluTBI vs. TBF in CR AML patients who underwent Haplo-SCT with PT-Cy in a retrospective comparison. We discovered that conditioning regimen did not have a significant effect on LFS, OS, and RI, but that CyFluTBI was associated with a substantial lower risk of NRM in older patients.

Source link: https://doi.org/10.1038/s41409-022-01674-x


Durability of and role of AKT in FGF7p urothelial protection against cyclophosphamide.

We previously identified a peptide that blocks urothelial apoptosis that is similar to full-length FGF7, but the effects of FGF7p on urothelial repair are uncertain. Also, although urothelial AKT activation downstream of FGF7p was linked to the anti-apoptotic effects, we have not explicitly investigated the role of AKT in mediating the cytoprotection. In mediating FGF7p's cytoprotective effects, our aim was to evaluate the effects of FGF7p on urothelial repair and the role of AKT signaling. We performed hematoxylin and eosin staining in FGF7p-treated mice 28 days after co-administering a systemic AKT antagonist with FGF7p-hysteride 24 h after cyclophosphamide. Some mice treated by vehicle-treated mice had ectopic lumenal progenitor cell markers, while FGF7p had none 28 days after cyclophosphamide was discontinued. In urothelium 24 hours after injury, aKT inhibitor's co-administration of an AKT inhibitor significantly abrogated FGF7p-driven AKT activation and cytoprotection.

Source link: https://doi.org/10.14814/phy2.15358


Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.

Bortezomib, a proteasome inhibitor, has been used in combination with cyclophosphamide and dexamethasone, demonstrating effectiveness in the treatment of newly diagnosed and relapsed AL amyloidosis. Ixazomib is the first oral PI to be approved in routine use, but it has yet to be evaluated in the upfront therapy setting. Patients with measurable disease and normal organ function were recruited by a newly diagnosed AL amyloidosis patient with measurable disease and normal organ function. In combination with cyclophosphamide and dexamethasone, the primary aim was to determine the hematologic response rate of ixazomib. Induction was 63% and included complete response in 11. 4% and very positive partial response in 37. 9% of patients, according to the overall hematologic response. The two-year PFS and OS were 74% and 78%, respectively, with a median follow-up of 29. 7 months for the living patients.

Source link: https://doi.org/10.1182/bloodadvances.2022007781


Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.

Daratumab/bortezomib/bortezomib/bortezomib/bortezomib/dexamethasone was safe and well tolerated in newly diagnosed multiple myeloma and relapsed multiple myeloma, according to the primary review of LYRA. Patients were given DARA + CyBorD induction, autologous stem cell transplantation, and 12 months of daratumab maintenance. According to 36-month survival statistics, the three-month progression-free survival rates were 76. 3 percent and 29. 8% for NDMM transplant and 29. 8% non-transplant patients, respectively. In 66% of NDMM patients, Grade 3/4 treatment-emergent adverse events occurred.

Source link: https://doi.org/10.1080/10428194.2022.2076847


The NLRP3 Inflammasome Inhibitor Dapansutrile Attenuates Cyclophosphamide-Induced Interstitial Cystitis.

Interstitial cystitis/bladder pain syndrome, also known as IC, is a medical disorder characterized by sterile inflammation in the bladder. However, the effects of NLRP3 inhibitors, including dapansutrile, on IC had not been investigated previously. Compared to mice that were not treated with CYP-treated mice treated with Dap, improved UB pathology and reduced inflammation scores, along with the number and number of mast cells and neutrophils, relative to mice that received CYP-treated mice. In the UB, induction of systemic and mucosal dendritic cells and a steady decrease in CXCR3+CD8+ T cells in the spleen and iliac lymph nodes, as well as reduced levels of systemic proinflammatory cytokines, as compared to CYP alone. These results, taken together, show that Dap suppresses IC by a decrease of CXCR3+T cells, mast cells, and neutrophils in the UB, as a protective measure, as shown by DCs.

Source link: https://doi.org/10.3389/fimmu.2022.903834


Tilapia Skin Peptides Ameliorate Cyclophosphamide-Induced Anxiety- and Depression-Like Behavior via Improving Oxidative Stress, Neuroinflammation, Neuron Apoptosis, and Neurogenesis in Mice.

Anxiety- and depression-like activity following chemotherapy therapy occurs in cancer patients with a high likelihood, and no specific therapeutics are available for treatment or prevention of this disorder. cyclophosphamide-induced anxiety and depression in mice was tested on tilapia skin peptides, a novel enzymatically hydrolyzed peptide mixture obtained from tilapia scraps here. Following the TSP therapy, behavioral changes in behavioral tests were dramatically improved. The expression of Iba-1 and the hippocampus of mice's hippocampus have normalized, showing that TSP can easily improve neuroinflammatory function in mouse hippocampuses. In the TSP group vs. the Model group, the TSP improved the apoptosis of hippocampal neurons in the CA1 and CA3 regions. The number of doublecortin positive cells in mice vs. the Model group was dramatically increased after administering 1000 mg/d TSP in mice.

Source link: https://doi.org/10.3389/fnut.2022.882175


Rapamycin maintains the primordial follicle pool and protects ovarian reserve against cyclophosphamide-induced damage.

Any abnormal follicle formation and subsequent depletion can irreversibly reduce the ovarian reserve, one of the most common chemotherapy-induced adverse effects in young patients with cancer. In a cyclophosphamide-treated mouse model, we investigated the effects of rapamycin on the activation and growth of ovarian follicles to determine its fertility-sparing therapeutic value. The ovarian reserve can be restored after CTX therapy because rapamycin's co-administration reduced primordial follicle loss and the formation of follicular cell apoptosis. We discovered that rapamycin dramatically reduced CTX-mediated overactivation of mTOR and its downstream molecules on analyzing the mTOR signaling pathway. These results indicate that rapamycin has the potential as an ovarian primordial follicle pool and preserving fertility in young female patients with cancer who are undergoing chemotherapy.

Source link: https://doi.org/10.1262/jrd.2022-001


Development and biological evaluation of protective effect of kidney targeted N-acetylated chitosan nanoparticles containing thymoquinone for the treatment of DNA damage in cyclophosphamide-induced haemorrhagic cystitis.

The most important component of Nigella sativa seeds, Thymoquinone, is reported to have an organ protective role by Nrf2 expression and the induction of Phase-II antioxidant enzymes. The acute onset of haematuria, bladder pain, and irritable bladder symptoms are among the common side effects of cyclophosphamide chemotherapy. During CYP-induced haemorrhagic cystitis, the aim of the present study was to investigate and compare the protective effects of thymoquinone and thymoquinone nanoparticles in the kidney against CYP-induced haemorrhagic cystitis. Compared to the TQ solution, the present review found that the TQ-NP prepared by ionic gelation technology provided kidney targeted delivery of TQ. TQ-NP has potent anti-oxidant, DNA safe, and cytokine inhibitory activity at much lower doses relative to a plain TQ solution, according to the present report.

Source link: https://doi.org/10.1016/j.ijbiomac.2022.06.070


Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: A retrospective analysis.

Patients are intolerant to high-dose GC monotherapy, according to the first choice for dermatomyositis complicated by interstitial lung disease. Patients in the CT cohort had CY in significantly fewer numbers than those in the TI cohort during treatment, despite having a TI cohort. Both 11 patients from the TI cohort and 14 patients from the CT cohort were relapsed. Patients of the TI cohort had an event-free survival longer than those of the CT cohort at the end of the 30-months. In addition, higher numbers of patients in the TI cohort survived without an event than those in the CT cohort. Patients of the TI cohort had herpes zoster and cytomegalovirus infections. For severe cases of DM-ILD, TAC is a recommended therapy for adequate GC with CY.

Source link: https://doi.org/10.1097/MD.0000000000029108


Polystyrene microplastics exacerbated liver injury from cyclophosphamide in mice: Insight into gut microbiota.

However, the effect of pre-consumed MPs on liver resistance to international robust stimuli remains unclear. In single CTX-treated mice, Slight liver injury was found, but in pre-drinking MPs mice, more significant liver histopathology, inflammation, and oxidative stress elicited by CTX were found. A Fecal microbiota transplantation trial was undertaken to more clearly demonstrate the vital role of MPs-altered gut bacteria in exaggerated liver responses to CTX stimulation.

Source link: https://doi.org/10.1016/j.scitotenv.2022.156668

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions